Terms ending in 2041
Every in-force patent on BioLineRx Ltd.'s record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,993,631 | Process for Manufacturing Peptide In force · High confidence | Biolinerx Ltd. and Biokine Therapeutics Ltd. | In force | High confidence | |
| US 12,257,285 | Composition of BL-8040 In force · High confidence | Biokine Therapeutics Ltd. | In force | High confidence | |
| US 12,268,725 | Composition of BL-8040 In force · High confidence | Biokine Therapeutics Ltd. | In force | High confidence |
3 of 3 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by BioLineRx Ltd..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.